Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924196 · ClinicalTrials.gov registry record
Natural History Study of Patients With Neurofibromatosis Type I
A clinical trial of Neurofibromatosis Type 1 and Plexiform Neurofibroma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 259
- Enrollment target
- 1
- Study location
NCT00924196 is a study of Neurofibromatosis Type 1 and Plexiform Neurofibroma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 259 participants, above the 145-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (79% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00924196, a study of Neurofibromatosis Type 1 and Plexiform Neurofibroma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 259 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The disease affects essentially every organ system. The natural course of NFI over time is poorly understood. For most patients the only treatment option is surgery. A better understanding of NF1 may be helpful for the design of future treatment studies. Objectives: To evaluate people with NF1 over 10 years in order to better understand the natural history of the disease. To characterize the patient population and to examine how NFI affects patients quality of life and function. Eligibility: Children, adolescents, and adults with NF1. Design: Participants have a comprehensive baseline evaluation including genetic testing, tumor imaging, pain and quality-of-life assessments, and neuropsychological, motor and endocrine evaluations. Patients are monitored every 6 months to every 3 years, depending on their individual findings at the baseline study. Tests may include the following, as appropriate: * Medical history, physical examination and blood tests. * Whole body and face photography to monitor visible deformities. * Neuropsychological testing, quality-of-life evaluations, motor function tests, endocrinologic evaluations, heart and lung function tests, hearing tests, bone density scans and other bone evaluations. * MRI and PET scans to detect and assess plexiform neurofibromas (tumors that arise from nerves and can cause serious problems), paraspinal neurofibromas (tumors that arise from nerves around the spine and can cause problems by compressing the spinal cord), and malignant peripheral nerve sheath tumors (a type of cancer that arises from a peripheral nerve or involves the sheath covering the nerve). * Eye exams, MRI scans and PET scans to evaluate optic pathway gliomas (tumors arising from the vision nerves or the brain areas for vision) and the chemicals w
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2008-02-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924196
The ClinicalTrials.gov registry entry for NCT00924196 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 145-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (79% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT00924196 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00924196 about?
NCT00924196 is a clinical study titled "Natural History Study of Patients With Neurofibromatosis Type I". Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The disease affects essentially every organ system. The natural course of NFI over time is poorly unde...
What is the current status of trial NCT00924196?
This trial is currently active not recruiting. The enrollment target is 259 participants. The study started on 2008-02-25.
What conditions does trial NCT00924196 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma, Malignant Peripheral Nerve Sheath Tumor, Neurofibroma, Optic Glioma.
Who is sponsoring clinical trial NCT00924196?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00924196 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
RECRUITING · NA
-
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
RECRUITING
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
RECRUITING · NA
-
Neurofibromatosis Type 1 Tumor Early Detection Study
RECRUITING
-
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
RECRUITING · Phase 2
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.